BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 23936419)

  • 1. Genistein inhibits prostate cancer cell growth by targeting miR-34a and oncogenic HOTAIR.
    Chiyomaru T; Yamamura S; Fukuhara S; Yoshino H; Kinoshita T; Majid S; Saini S; Chang I; Tanaka Y; Enokida H; Seki N; Nakagawa M; Dahiya R
    PLoS One; 2013; 8(8):e70372. PubMed ID: 23936419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long Non-Coding RNA HOTAIR Regulates the Proliferation, Self-Renewal Capacity, Tumor Formation and Migration of the Cancer Stem-Like Cell (CSC) Subpopulation Enriched from Breast Cancer Cells.
    Deng J; Yang M; Jiang R; An N; Wang X; Liu B
    PLoS One; 2017; 12(1):e0170860. PubMed ID: 28122024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of endonuclease domain-containing 1 as a novel tumor suppressor in prostate cancer.
    Qiu J; Peng S; Si-Tu J; Hu C; Huang W; Mao Y; Qiu W; Li K; Wang D
    BMC Cancer; 2017 May; 17(1):360. PubMed ID: 28532481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent Inhibition of miR-34b on Migration and Invasion in Metastatic Prostate Cancer Cells by Regulating the TGF-β Pathway.
    Fang LL; Sun BF; Huang LR; Yuan HB; Zhang S; Chen J; Yu ZJ; Luo H
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29257105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prenatal Cadmium Exposure Alters Proliferation in Mouse CD4
    McCall JL; Varney ME; Rice E; Dziadowicz SA; Hall C; Blethen KE; Hu G; Barnett JB; Martinez I
    Front Immunol; 2021; 12():720635. PubMed ID: 35087510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of lncRNA SNHG12 on the proliferation, migration and invasiveness of prostate cancer cells by regulating E2F5 expression].
    Xu SL; Gu XH; Feng Q
    Zhonghua Nan Ke Xue; 2023 Feb; 29(2):113-119. PubMed ID: 37847082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genistein treatment duration effects biomarkers of cell motility in human prostate.
    Zhang H; Gordon R; Li W; Yang X; Pattanayak A; Fowler G; Zhang L; Catalona WJ; Ding Y; Xu L; Huang X; Jovanovic B; Kelly DL; Jiang H; Bergan R
    PLoS One; 2019; 14(3):e0214078. PubMed ID: 30917169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-30e inhibits adhesion, migration, invasion and cell cycle progression of prostate cancer cells via inhibition of the activation of the MAPK signaling pathway by downregulating CHRM3.
    Zheng XM; Zhang P; Liu MH; Chen P; Zhang WB
    Int J Oncol; 2019 Feb; 54(2):443-454. PubMed ID: 30483762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of lncRNA HOTAIR sensitizes breast cancer cells to ionizing radiation through activating miR-218.
    Hu X; Ding D; Zhang J; Cui J
    Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30429228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting HOXA11-AS to mitigate prostate cancer via the glycolytic metabolism: In vitro and in vivo.
    Zhang J; Li S; Zhang M; Wang Z; Xing Z
    J Cell Mol Med; 2024 Apr; 28(8):e18227. PubMed ID: 38520207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises.
    Li WJ; Wang Y; Liu X; Wu S; Wang M; Turowski SG; Spernyak JA; Tracz A; Abdelaal AM; Sudarshan K; Puzanov I; Chatta G; Kasinski AL; Tang DG
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genistein inhibits the contact-stimulated migration of prostate cancer cells.
    Miękus K; Madeja Z
    Cell Mol Biol Lett; 2007 Sep; 12(3):348-61. PubMed ID: 17297558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of proliferation, invasion, and migration of prostate cancer cells by downregulating elongation factor-1alpha expression.
    Zhu G; Yan W; He HC; Bi XC; Han ZD; Dai QS; Ye YK; Liang YX; Wang J; Zhong W
    Mol Med; 2009; 15(11-12):363-70. PubMed ID: 19707524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. rAAV-based and intraprostatically delivered miR-34a therapeutics for efficient inhibition of prostate cancer progression.
    Ai J; Li J; Su Q; Ma H; He R; Wei Q; Li H; Gao G
    Gene Ther; 2022 Aug; 29(7-8):418-424. PubMed ID: 34226687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and evaluation of the antiproliferative activity of hydantoin-derived antiandrogen-genistein conjugates.
    George A; Raji I; Cinar B; Kucuk O; Oyelere AK
    Bioorg Med Chem; 2018 May; 26(8):1481-1487. PubMed ID: 29456113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of microRNAs and long non-coding RNAs in the pathology, diagnosis, and management of melanoma.
    Aftab MN; Dinger ME; Perera RJ
    Arch Biochem Biophys; 2014 Dec; 563():60-70. PubMed ID: 25065585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long non-coding RNA HOTAIR regulates proliferation, migration and invasion of human cervical cancer cells by modulating expression of MAPK1.
    Liu H; Liu J; Zhao G
    Arch Med Sci; 2020; 16(5):1158-1165. PubMed ID: 32864005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of MicroRNA-21 in Prostate Cancer Progression and Metastasis: Molecular Mechanisms to Therapeutic Targets.
    Singh VK; Rajak N; Singh Y; Singh AK; Giri R; Garg N
    Ann Surg Oncol; 2024 May; ():. PubMed ID: 38758485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-410 Is a Key Regulator of Epithelial-to-Mesenchymal Transition with Biphasic Role in Prostate Cancer.
    Asante DM; Sreekumar A; Nathani S; Lee TJ; Sharma A; Patel N; Simmons MN; Saini S
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing folate-conjugated miR-34a therapeutic for prostate cancer treatment: Challenges and promises.
    Li WJ; Wang Y; Liu X; Wu S; Wang M; Turowski SG; Spernyak JA; Tracz A; Abdelaal AM; Sudarshan K; Puzanov I; Chatta G; Kasinski AL; Tang DG
    bioRxiv; 2024 Jan; ():. PubMed ID: 38045265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.